Neurocrine Biosciences, Inc.

Good day, everyone, and welcome to today's Neurocrine Biosciences Report's fourth quarter and year-end results. At this time, all participants are in a listen-only mode. Later, you'll have the opportunity to ask questions during the question-and-answer period. You may register to ask a question at any time by pressing star 1 on your touch-tone phone. Please note this call may be recorded and I will be standing by should you need any assistance. It is now my pleasure to turn the call over to Todd Tischler, Vice President of Investor Relations. Please go ahead.

Thank you, and a good Monday morning to everyone. Welcome to NERCRN's fourth quarter and full year 2022 earnings call. I'm joined by Kevin Gorman, our Chief Executive Officer, Matt Abernathy, our Chief Financial Officer, Irie Roberts, our Chief Medical Officer, Eric Benevich, our Chief Commercial Officer, and Kyle Gano, our Chief Business Development and Strategy Officer. During this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. We'll be jumping into Q&A after prepared remarks, and as is customary, we will do our best to get to all of your questions. With that, I'll turn things over to Kevin.

Thank you, Todd, and good morning. Over the last several years, we have launched a number of initiatives to bring in resident TD patients and relieve their suffering. Now, many of those initiatives have been very successful, as evidenced most recently by the growth of Ingress in 2022, as we announced this morning. We're going to continue to build on those efforts and anticipate continued meaningful growth in 2023 out into the foreseeable future. Now, the initiatives that are most obvious to you are the expansion of our sales force and our direct-to-consumer advertising. What is less obvious but very important are all the other teams within the company that are force multipliers in making sure TD sufferers are appropriately treated. Many of these efforts are aimed at educating healthcare professionals, their staff, payers, and their medical advisors, and importantly, for the first time, patients have groups advocating for the disease and their care. Again, these efforts have yielded significant results for sufferers of TD to date, and we will continue that momentum because the vast majority remain undiagnosed and untreated. Switching gears, we have a deep and diversified portfolio of mid- and late-stage medicines that will have important readouts this year and into 2024. We've invested meaningfully in our research and development such that multiple new molecules will enter the clinic each year. on a consistent basis to ensure a product flow into the future. I'll stop there, and with that, turn it over to Matt.